Sex steroids and sex hormone-binding globulin in postmenopausal women with nonalcoholic fatty liver disease (original) (raw)
Polyzos SA, Kountouras J, Zavos C, 2009 Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 72: 299–314. Article Google Scholar
Vernon G, Baranova A, Younossi ZM, 2011 Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34: 274–285. ArticleCASPubMed Google Scholar
Polyzos SA, Kountouras J, Zavos C, Deretzi G, 2012 Nonalcoholic fatty liver disease: Multimodal treatment options for a pathogenetically multiple-hit disease. J Clin Gastroenterol 46: 272–284. ArticlePubMed Google Scholar
Baranova A, Tran TP, Birerdinc A, Younossi ZM, 2011 Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 33: 801–814. ArticleCASPubMed Google Scholar
Vassilatou E, Lafoyianni S, Vryonidou A, et al, 2010 Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod 25: 212–220. ArticleCASPubMed Google Scholar
Shin JY, Kim SK, Lee MY, et al, 2011 Serum sex hormone-binding globulin levels are independently associated with nonalcoholic fatty liver disease in people with type 2 diabetes. Diabetes Res Clin Pract 94: 156–162. ArticleCASPubMed Google Scholar
Mojiminiyi OA, Safar FH, Al RH, Diejomaoh M, 2010 Variations in alanine aminotransferase levels within the normal range predict metabolic and androgenic phenotypes in women of reproductive age. Scand J Clin Lab Invest 70: 554–560. ArticleCASPubMed Google Scholar
Kauffman RP, Baker TE, Baker V, Kauffman MM, Castracane VD, 2010 Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: do androgens play a role? Gynecol Endocrinol 26: 39–46. ArticleCASPubMed Google Scholar
Tian GX, Sun Y, Pang CJ, et al, 2012 Oestradiol is a protective factor for non-alcoholic fatty liver disease in healthy men. Obes Rev 13: 381–387. ArticleCASPubMed Google Scholar
Gutierrez-Grobe Y, Ponciano-Rodriguez G, Ramos MH, Uribe M, Mendez-Sanchez N, 2010 Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol 9: 402–409. PubMed Google Scholar
Tan S, Bechmann LP, Benson S, et al, 2010 Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. J Clin Endocrinol Metab 95: 343–348. ArticleCASPubMed Google Scholar
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC, 1985 Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419. ArticleCASPubMed Google Scholar
Vermeulen A, Verdonck L, Kaufman JM, 1999 A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84: 3666–3672. ArticleCASPubMed Google Scholar
Kleiner DE, Brunt EM, Van NM, et al, 2005 Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313–1321. ArticlePubMed Google Scholar
Brand JS, van dT, I, Grobbee DE, Emmelot-Vonk MH, van der Schouw YT, 2011 Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol 40: 189–207. ArticlePubMed Google Scholar
Selva DM, Hogeveen KN, Innis SM, Hammond GL, 2007 Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone-binding globulin gene. J Clin Invest 117: 3979–3987. PubMedPubMed CentralCAS Google Scholar
Yasui T, Tomita J, Miyatani Y, et al, 2007 Associations of adiponectin with sex hormone-binding globulin levels in aging male and female populations. Clin Chim Acta 386: 69–75. ArticleCASPubMed Google Scholar
Laaksonen DE, Niskanen L, Punnonen K, et al, 2003 Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol 149: 601–608. ArticleCASPubMed Google Scholar
McKenzie J, Fisher BM, Jaap AJ, Stanley A, Paterson K, Sattar N, 2006 Effects of HRT on liver enzyme levels in women with type 2 diabetes: a randomized placebo-controlled trial. Clin Endocrinol (Oxf) 65: 40–44. ArticleCAS Google Scholar
Kim MH, Kang KS, Lee YS, 2010 The inhibitory effect of genistein on hepatic steatosis is linked to visceral adipocyte metabolism in mice with diet-induced nonalcoholic fatty liver disease. Br J Nutr 104: 1333–1342. ArticleCASPubMed Google Scholar
Kamada Y, Kiso S, Yoshida Y, et al, 2011 Estrogen deficiency worsens steatohepatitis in mice fed high-fat and high-cholesterol diet. Am J Physiol Gastrointest Liver Physiol 301: G1031–G1043. ArticleCASPubMed Google Scholar
Fukui M, Senmaru T, Hasegawa G, et al, 2011 17beta-Estradiol attenuates saturated fatty acid diet-induced liver injury in ovariectomized mice by up-regulating hepatic senescence marker protein-30. Biochem Biophys Res Commun 415: 252–257. ArticleCASPubMed Google Scholar
Chow JD, Jones ME, Prelle K, Simpson ER, Boon WC, 2011 A selective estrogen receptor alpha agonist ameliorates hepatic steatosis in the male aromatase knockout mouse. J Endocrinol 210: 323–334. ArticleCASPubMed Google Scholar
Giannitrapani L, Soresi M, La SE, Cervello M, D’Alessandro N, Montalto G, 2006 Sex hormones and risk of liver tumor. Ann N Y Acad Sci 1089: 228–236. ArticleCASPubMed Google Scholar
Kountouras J, Boura P, Karolides A, Zaharioudaki E, Tsapas G, 1995 Recombinant a2 interferon (a-IFN) with chemo-hormonal therapy in patients with hepatocellular carcinoma (HCC). Hepatogastroenterology 42: 31–36. PubMedCAS Google Scholar
Yin PH, Lee HC, Chau GY, et al, 2004 Polymorphisms of estrogen-metabolizing genes and risk of hepatocellular carcinoma in Taiwan females. Cancer Lett 212: 195–201. ArticleCASPubMed Google Scholar
Koehler E, Swain J, Sanderson S, Krishnan A, Watt K, Charlton M, 2012 Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients. Liver Int 32: 279–286. ArticleCASPubMed Google Scholar
Sumida Y, Yonei Y, Kanemasa K, et al, 2010 Lower circulating levels of dehydroepiandrosterone, independent of insulin resistance, is an important determinant of severity of non-alcoholic steatohepatitis in Japanese patients. Hepatol Res 40: 901–910. ArticleCASPubMed Google Scholar
Charlton M, Angulo P, Chalasani N, et al, 2008 Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology 47: 484–492. ArticleCASPubMedPubMed Central Google Scholar
Ahmed A, Rabbitt E, Brady T, et al, 2012 A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease. PLos One 7: e29531. ArticleCASPubMedPubMed Central Google Scholar
Konopelska S, Kienitz T, Hughes B, et al, 2009 Hepatic 11beta-HSD1 mRNA expression in fatty liver and nonalcoholic steatohepatitis. Clin Endocrinol (Oxf) 70: 554–560. ArticleCAS Google Scholar
Bedogni G, Bellentani S, Miglioli L, et al, 2006 The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6: 33. ArticleCASPubMedPubMed Central Google Scholar
Vongsuvanh R, George J, McLeod D, van der PD, 2012 Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease. J Hepatol 57: 392–398. ArticlePubMed Google Scholar
Ly LP, Sartorius G, Hull L, et al, 2010 Accuracy of calculated free testosterone formulae in men. Clin Endocrinol (Oxf) 73: 382–388. ArticleCAS Google Scholar